Systematic review finds shockwave therapy offers no consistent benefit for Achilles tendinopathy compared to controls

To evaluate the effects of shockwave therapy (SWT) for Achilles tendinopathy compared to sham-SWT as a monotherapy or co-intervention or no treatment. Intervention systematic review with meta-analysis of randomized controlled trials (RCTs). AMED, CINAHL, Web of Science, MEDLINE, EMBASE, SPORTDiscus, Cochrane CENTRAL, clinical trial registries, and gray literature were searched between February 14 and February 24, 2025. Criteria included RCTs assessing radial or focused SWT (with or without co-interventions) in adults with Achilles tendinopathy. We conducted a random-effects meta-analysis. We assessed risk of bias using the Cochrane Risk of Bias 2 tool and certainty of evidence using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) framework. Nine RCTs (n = 557) were included. For insertional Achilles tendinopathy, SWT showed no clinically meaningful benefit over sham (low-moderate certainty), with consistent findings across all outcomes and sensitivity/subgroup analyses. For midportion Achilles tendinopathy, all meta-analyses (very low and moderate certainty) showed no significant differences in disability or pain between SWT and control interventions at all timepoints. There was very low-certainty evidence of a clinically meaningful effect of radial SWT on short- and long-term improvements in disability and pain compared to sham or wait-and-see controls. One trial (midportion Achilles tendinopathy) showed benefit over sham-SWT but did not report success of participant blinding. Subgroup analyses revealed no clear advantage for either radial or focused SWT. Two Achilles tendon ruptures were reported following focused SWT. There was no clinically meaningful benefit of SWT in pain and disability for Achilles tendinopathy, with evidence ranging from very low to moderate certainty. Because most effect estimates are based on very low- and low-certainty data, the true effects may change with future high-quality trials. At present, SWT should not be considered a routine treatment for either insertional or midportion Achilles tendinopathy, and alternative treatments should be prioritized. .